Secondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonates

Osteoporosis International

Volumn 22, Issue 6, 2011, Pages 1821-1828

  Ojeda Bruno, S ^a   Naranjo, A ^b   Francisco Hernandez F ^a   Erausquin, C ^a   Rua Figueroa I ^a   Quevedo, J C ^a   Rodriguez Lozano C ^a  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

Alendronate; Bisphosphonates; Compliance; Fragility fracture; Osteoporosis; Telephone survey

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; STRONTIUM RANELATE; THYROTROPIN; TIBOLONE; VITAMIN D;

ADULT; AGED; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DIET; DRUG EFFICACY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EMERGENCY WARD; EXERCISE; FALLING; FEMALE; FEMUR NECK FRACTURE; FOLLOW UP; FOREARM FRACTURE; FRAGILITY FRACTURE; HEALTH PROGRAM; HEALTH SURVEY; HIP; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SECONDARY PREVENTION; SHOULDER FRACTURE; TELEPHONE; VERTEBRA BODY; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; EMERGENCY SERVICE, HOSPITAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PROGRAM EVALUATION; PROSPECTIVE STUDIES; RECURRENCE; SECONDARY PREVENTION; SPAIN;

EID: 79960019292     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1414-z     Document Type: Conference Paper

References (42)

1. Cuddihy MT, Gabriel SE, Crowson CS, O'Fallon WM, Melton LJ 3rd (1999) Forearm fractures as predictors of subsequent osteoporotic fractures. Osteoporos Int 9:469-475 (Pubitemid 29348560)
2. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320-323 (Pubitemid 32095035)
3. Nymark T, Lauritsen JM, Ovesen O, Röck ND, Jeune B (2006) Short time-frame from first to second hip fracture in the Funen county hip fracture study. Osteoporos Int 17:1353-1357 (Pubitemid 44127322)
4. Johnell O, Jönsson B, Jönsson L, Black D (2003) Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305-314 (Pubitemid 36403435)
5. Levis S, Quandt SA, Thompson D, Scott J, Schneider DL, Ross PD, Black D, Suryawanshi S, Hochberg M, Yates J (2002) Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc 50:409-415 (Pubitemid 34229393)
6. Chrischilles EA, Dasbach EJ, Rubenstein LM, Cook JR, Tabor HK, Black DM (2001) The effect of alendronate on fracturerelated healthcare utilization and costs: the fracture intervention trial. Osteoporos Int 12:654-660 (Pubitemid 32889166)
7. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT research group. J Clin Endocrinol Metab 85:4118-4124 (Pubitemid 32055362)
8. Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95:1174-1181
9. Pal B (1999) Questionnaire survey of advice given to patients with fractures. BMJ 318:500-501 (Pubitemid 29188993)
10. Torgerson DJ, Dolan P (1999) Advice given to patients with fractures. BMJ 318:1698
11. Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767-778 (Pubitemid 39361946)
12. Jones TJ, Petrella RJ, Crilly R (2008) Determinants of persistence with weekly bisphosphonates in patients with osteoporosis. J Rheumatol 35:1865-1873
13. Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023-1031 (Pubitemid 47019996)
14. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. May Clin Proc 81:1013-1022 (Pubitemid 44175011)
15. Sunyecz JA, Mucha L, Baser O, Barr CE, Amonkar MM (2008) Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int 19:1421-1419
16. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137-1141 (Pubitemid 24985932)
17. Andrade SE, Majumdar SR, Chan KA, Buist DS, Go AS, Goodman M, Smith DH, Platt R, Gurwitz JH (2003) Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 163:2052-1057
18. Rozental TD, Makhni EC, Day CS, Bouxsein ML (2008) Improving evaluation and treatment for osteoporosis following distal radial fractures. A prospective randomized intervention. J Bone Joint Surg Am 90:953-961 (Pubitemid 351632637)
19. Bessette L, Ste-Marie LG, Jean S, Davison KS, Beaulieu M, Baranci M, Bessant J, Brown JP (2008) The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporosis Int 19:79-86 (Pubitemid 350198056)
20. Feldstein A, Elmer PJ, Smith DH, Herson M, Orwoll E, Chen C, Aickin M, Swain MC (2006) Electronic medical record reminder improves osteoporosis management after a fracture: a randomized, controlled trial. J Am Geriatr Soc 54:450-457 (Pubitemid 43327157)
21. Hawker G, Ridout R, Ricupero M, Jaglal S, Bogoch E (2003) The impact of a simple fracture clinic intervention in improving the diagnosis and treatment of osteoporosis in fragility fracture patients. Osteoporos Int 14:171-178 (Pubitemid 40824235)
22. Majumdar SR, Rowe BH, Folk D, Johnson JA, Holroyd BH, Morrish DW, Maksymowych WP, Steiner IP, Harley CH, Wirzba BJ, Hanley DA, Blitz S, Russell AS (2004) A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med 141:366-373
23. Charalambous CP, Kumar S, Tryfonides M, Rajkumar P, Hirst P (2002) Management of osteoporosis in an orthopaedic department: audit improves practice. Int J Clin Pract 56:620-621 (Pubitemid 35256399)
24. Cuddihy MT, Amadio PC, Gabriel SE, Pankratz VS, Kurland RL, Melton LJ 3rd (2004) A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture. Osteoporos Int 15:695-700 (Pubitemid 39222651)
25. McLellan AR, Gallacher SJ, Fraser M, McQuillian C (2003) The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int 14:1028-1034 (Pubitemid 40824270)
26. Bogoch ER, Elliot-Gibson V, Beaton DE, Jamal SA, Josse RG, Murray TM (2006) Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am 88:25-34 (Pubitemid 43062769)
27. Ward SE, Laughren JJ, Escott BG, Elliot-Gibson V, Bogoch ER, Beaton DE (2007) A program with a dedicated coordinator improved chart documentation of osteoporosis after fragility fracture. Osteoporos Int 18:1127-1136 (Pubitemid 47019999)
28. Harrington JT, Lease J (2007) Osteoporosis disease management for fragility fracture patients: new understandings based on three years' experience with an osteoporosis care service. Arthritis Rheum 57:1502-1506 (Pubitemid 350308850)
29. Sander B, Elliot-Gibson V, Beaton DE, Bogoch ER, Maetzel A (2008) A coordinator program in post-osteoporosis management improves outcomes and saves costs. J Bone Joint Surg Am 90:1197-1205 (Pubitemid 351778125)
30. Harrington JT, Deal CL (2006) Successes and failures in improving osteoporosis care after fragility fracture: results of a multiple-site clinical improvement project. Arthritis Rheum 55:724-728 (Pubitemid 44619185)
31. Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645-1652 (Pubitemid 44477625)
32. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487-497 (Pubitemid 41127293)
33. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493-1501 (Pubitemid 350211697)
34. Kertes J, Dushenat M, Vesterman JL, Lemberger J, Bregman J, Friedman N (2008) Factors contributing to compliance with osteoporosis medication. Isr Med Assoc J 10:207-213 (Pubitemid 351649619)
35. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM (2006) Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28:236-242 (Pubitemid 44287822)
36. Payer J, Killinger Z, Sulková I, Celec P (2008) Preferences of patients receiving bisphosphonates-how to influence the therapeutic adherence. Biomed Pharmacother 62:122-124 (Pubitemid 351215813)
37. Weiss TW, McHorney CA (2007) Osteoporosis medication profile preference: results from the PREFER-US study. Health Expect 10:211-213
38. Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145-155
39. Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17:1638-1644 (Pubitemid 44477624)
40. McHorney CA, Schousboe JT, Cline RR, Weiss TW (2007) The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin 23:3137-3252
41. Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117-1123 (Pubitemid 38368399)
42. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2: CD000011